Drugs / ∆9-tetrahydrocannabinol
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06099379 | Jun 2024 → Jul 2026 overdue | cannabis dependence, thrombocytopenia 3 | University of Montreal Hospital Centre (CHUM) | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ∆9-tetrahydrocannabinol | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06099379 ↗ |
| Modality | Other / unclassified | “Phytocannabinoids from plant inflorescences (CBD and THC dominant)” NCT06099379 ↗ |
| Route | Inhaled | “inhaled” NCT06099379 ↗ |